Aquestive Therapeutics Inc. (AQST)’s Financial Results Comparing With Dova Pharmaceuticals Inc. (NASDAQ:DOVA)

Aquestive Therapeutics Inc. (NASDAQ:AQST) and Dova Pharmaceuticals Inc. (NASDAQ:DOVA), both competing one another are Biotechnology companies. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aquestive Therapeutics Inc. 62.80M 2.55 58.10M -2.81 0.00
Dova Pharmaceuticals Inc. 7.51M 28.42 62.25M -2.27 0.00

Demonstrates Aquestive Therapeutics Inc. and Dova Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.


Table 2 has Aquestive Therapeutics Inc. and Dova Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aquestive Therapeutics Inc. -92.52% 0% 0%
Dova Pharmaceuticals Inc. -828.89% -63.8% -50.2%


3.6 and 3.4 are the respective Current Ratio and a Quick Ratio of Aquestive Therapeutics Inc. Its rival Dova Pharmaceuticals Inc.’s Current and Quick Ratios are 7.5 and 7.4 respectively. Dova Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Aquestive Therapeutics Inc.

Insider & Institutional Ownership

Institutional investors owned 65.2% of Aquestive Therapeutics Inc. shares and 47.7% of Dova Pharmaceuticals Inc. shares. Insiders owned 9.8% of Aquestive Therapeutics Inc. shares. Competitively, 44.9% are Dova Pharmaceuticals Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aquestive Therapeutics Inc. -3.38% -53.66% -55.54% 0% 0% -48.29%
Dova Pharmaceuticals Inc. 3.62% -17.48% -33.99% -47.8% -48.29% -46.39%

For the past year Dova Pharmaceuticals Inc. has weaker performance than Aquestive Therapeutics Inc.


On 6 of the 10 factors Aquestive Therapeutics Inc. beats Dova Pharmaceuticals Inc.

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. Its proprietary product candidates that are in development comprise AQST-203, a buccally, an administered soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; AQST-120, an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy; and AQST-117, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's development products also include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; AQST-305, a buccal film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors; APL-130277, a sublingual film formulation of apomorphine to treat episodic off-periods in Parkinson's disease; AQST-119, an oral soluble film formulation of tadalafil to treat erectile dysfunction; and AQST-306, a film formulation of edaravone. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia diseases. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver diseases. The company was founded in 2016 and is based in Durham, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.